- Home
- GSK vs ZTS Comparison
GSK vs ZTS Comparison
Compare GSK & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSK
- ZTS
- Stock Information
- Founded
- GSK 1715
- ZTS 1952
- Country
- GSK United Kingdom
- ZTS United States
- Employees
- GSK N/A
- ZTS N/A
- Industry
- GSK Biotechnology: Pharmaceutical Preparations
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- GSK Health Care
- ZTS Health Care
- Exchange
- GSK Nasdaq
- ZTS Nasdaq
- Market Cap
- GSK 81.9B
- ZTS 66.2B
- IPO Year
- GSK N/A
- ZTS 2013
- Fundamental
- Price
- GSK $43.65
- ZTS $142.28
- Analyst Decision
- GSK Hold
- ZTS Buy
- Analyst Count
- GSK 2
- ZTS 8
- Target Price
- GSK N/A
- ZTS $200.25
- AVG Volume (30 Days)
- GSK 5.9M
- ZTS 3.1M
- Earning Date
- GSK 10-29-2025
- ZTS 11-04-2025
- Dividend Yield
- GSK 3.71%
- ZTS 1.41%
- EPS Growth
- GSK N/A
- ZTS 14.10
- EPS
- GSK 1.13
- ZTS 5.82
- Revenue
- GSK $43,336,073,439.00
- ZTS $9,385,000,000.00
- Revenue This Year
- GSK $5.50
- ZTS $3.88
- Revenue Next Year
- GSK $5.21
- ZTS $5.91
- P/E Ratio
- GSK $38.60
- ZTS $24.45
- Revenue Growth
- GSK 0.59
- ZTS 5.27
- 52 Week Low
- GSK $31.72
- ZTS $139.34
- 52 Week High
- GSK $45.59
- ZTS $196.55
- Technical
- Relative Strength Index (RSI)
- GSK 62.67
- ZTS 39.07
- Support Level
- GSK $43.10
- ZTS $142.15
- Resistance Level
- GSK $44.23
- ZTS $145.22
- Average True Range (ATR)
- GSK 0.88
- ZTS 2.75
- MACD
- GSK 0.07
- ZTS -0.04
- Stochastic Oscillator
- GSK 69.13
- ZTS 31.06
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.